Story thread · 3 reports / 3 sources
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharmadive.com · 20m
How the coverage leans
Across 3 sources · syndicated copies counted once
The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.
First report: Merck, Daiichi pull US application for second partnered cancer therapy — reuters.com, 2d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.